Suppr超能文献

HIV-1 储存库细胞的免疫靶向:消除策略和治愈的途径。

Immune targeting of HIV-1 reservoir cells: a path to elimination strategies and cure.

机构信息

Infectious Disease Division, Brigham and Women's Hospital, Boston, MA, USA.

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.

出版信息

Nat Rev Microbiol. 2024 Jun;22(6):328-344. doi: 10.1038/s41579-024-01010-8. Epub 2024 Feb 9.

Abstract

Successful approaches for eradication or cure of HIV-1 infection are likely to include immunological mechanisms, but remarkably little is known about how human immune responses can recognize and interact with the few HIV-1-infected cells that harbour genome-intact viral DNA, persist long term despite antiretroviral therapy and represent the main barrier to a cure. For a long time regarded as being completely shielded from host immune responses due to viral latency, these cells do, on closer examination with single-cell analytic techniques, display discrete footprints of immune selection, implying that human immune responses may be able to effectively engage and target at least some of these cells. The failure to eliminate rebound-competent virally infected cells in the majority of persons likely reflects the evolution of a highly selected pool of reservoir cells that are effectively camouflaged from immune recognition or rely on sophisticated approaches for resisting immune-mediated killing. Understanding the fine-tuned interplay between host immune responses and viral reservoir cells will help to design improved interventions that exploit the immunological vulnerabilities of HIV-1 reservoir cells.

摘要

成功根除或治愈 HIV-1 感染的方法可能包括免疫机制,但人们对人类免疫反应如何识别和与少数携带完整基因组病毒 DNA 的 HIV-1 感染细胞相互作用知之甚少,这些细胞尽管接受了抗逆转录病毒治疗,但仍能长期存在,是治愈的主要障碍。这些细胞由于病毒潜伏而长期被认为完全免受宿主免疫反应的影响,但通过单细胞分析技术的更仔细检查,它们确实显示出免疫选择的离散痕迹,这意味着人类免疫反应可能能够有效地参与并针对这些细胞中的至少一些。在大多数人中未能消除具有反弹能力的病毒感染细胞,可能反映了储备细胞的高度选择池的演变,这些细胞有效地逃避了免疫识别,或者依靠复杂的方法来抵抗免疫介导的杀伤。了解宿主免疫反应和病毒储备细胞之间的精细相互作用将有助于设计改进的干预措施,利用 HIV-1 储备细胞的免疫脆弱性。

相似文献

1
Immune targeting of HIV-1 reservoir cells: a path to elimination strategies and cure.
Nat Rev Microbiol. 2024 Jun;22(6):328-344. doi: 10.1038/s41579-024-01010-8. Epub 2024 Feb 9.
2
Targeting the Latent Reservoir for HIV-1.
Immunity. 2018 May 15;48(5):872-895. doi: 10.1016/j.immuni.2018.04.030.
3
Activation of Latent HIV-1 T Cell Reservoirs with a Combination of Innate Immune and Epigenetic Regulators.
J Virol. 2019 Oct 15;93(21). doi: 10.1128/JVI.01194-19. Print 2019 Nov 1.
5
Type 1-programmed dendritic cells drive antigen-specific latency reversal and immune elimination of persistent HIV-1.
EBioMedicine. 2019 May;43:295-306. doi: 10.1016/j.ebiom.2019.03.077. Epub 2019 Apr 2.
7
Phenotypic signatures of immune selection in HIV-1 reservoir cells.
Nature. 2023 Feb;614(7947):309-317. doi: 10.1038/s41586-022-05538-8. Epub 2023 Jan 4.
8
Phenotypic analysis of the unstimulated in vivo HIV CD4 T cell reservoir.
Elife. 2020 Sep 29;9:e60933. doi: 10.7554/eLife.60933.
10
Differentiating Immune Cell Targets in Gut-Associated Lymphoid Tissue for HIV Cure.
AIDS Res Hum Retroviruses. 2017 Nov;33(S1):S40-S58. doi: 10.1089/AID.2017.0153.

引用本文的文献

3
Aquarius helicase facilitates HIV-1 integration into R-loop enriched genomic regions.
Nat Microbiol. 2025 Aug 20. doi: 10.1038/s41564-025-02089-2.
4
No associations between HIV reservoir and inflammation in long-term virally suppressed dolutegravir-based ART-treated individuals.
Front Immunol. 2025 Jul 28;16:1628086. doi: 10.3389/fimmu.2025.1628086. eCollection 2025.
6
Applications and limitations of the passenger hypothesis for HIV reservoir persistence and cure.
J Virol. 2025 Jul 22;99(7):e0071425. doi: 10.1128/jvi.00714-25. Epub 2025 Jun 4.
7
Distinct viral reservoirs and immune signatures in individuals on long-term antiretroviral therapy with perinatally acquired HIV-1.
Cell Rep Med. 2025 Jun 17;6(6):102150. doi: 10.1016/j.xcrm.2025.102150. Epub 2025 May 29.
10
Heat shock protein 90 is a chaperone regulator of HIV-1 latency.
PLoS Pathog. 2025 Apr 1;21(4):e1012524. doi: 10.1371/journal.ppat.1012524. eCollection 2025 Apr.

本文引用的文献

2
Viral and host mediators of non-suppressible HIV-1 viremia.
Nat Med. 2023 Dec;29(12):3212-3223. doi: 10.1038/s41591-023-02611-1. Epub 2023 Nov 13.
3
Persistence of intact HIV-1 proviruses in the brain during antiretroviral therapy.
Elife. 2023 Nov 8;12:RP89837. doi: 10.7554/eLife.89837.
5
AZD5582 plus SIV-specific antibodies reduce lymph node viral reservoirs in antiretroviral therapy-suppressed macaques.
Nat Med. 2023 Oct;29(10):2535-2546. doi: 10.1038/s41591-023-02570-7. Epub 2023 Oct 2.
8
Impact of misclassified defective proviruses on HIV reservoir measurements.
Nat Commun. 2023 Jul 13;14(1):4186. doi: 10.1038/s41467-023-39837-z.
9
Anti-V1/V3-glycan broadly HIV-1 neutralizing antibodies in a post-treatment controller.
Cell Host Microbe. 2023 Aug 9;31(8):1275-1287.e8. doi: 10.1016/j.chom.2023.06.006. Epub 2023 Jul 10.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验